GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Foghorn Therapeutics Inc (NAS:FHTX) » Definitions » PS Ratio
中文

Foghorn Therapeutics (Foghorn Therapeutics) PS Ratio : 6.40 (As of Apr. 25, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Foghorn Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Foghorn Therapeutics's share price is $5.21. Foghorn Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.81. Hence, Foghorn Therapeutics's PS Ratio for today is 6.40.

The historical rank and industry rank for Foghorn Therapeutics's PS Ratio or its related term are showing as below:

FHTX' s PS Ratio Range Over the Past 10 Years
Min: 3.64   Med: 69.19   Max: 5176
Current: 6.44

During the past 6 years, Foghorn Therapeutics's highest PS Ratio was 5176.00. The lowest was 3.64. And the median was 69.19.

FHTX's PS Ratio is ranked better than
59.94% of 991 companies
in the Biotechnology industry
Industry Median: 8.98 vs FHTX: 6.44

Foghorn Therapeutics's Revenue per Sharefor the three months ended in Dec. 2023 was $0.14. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.81.

During the past 12 months, the average Revenue per Share Growth Rate of Foghorn Therapeutics was 76.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was 175.30% per year.

During the past 6 years, Foghorn Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 175.30% per year. The lowest was 175.30% per year. And the median was 175.30% per year.

Back to Basics: PS Ratio


Foghorn Therapeutics PS Ratio Historical Data

The historical data trend for Foghorn Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Foghorn Therapeutics PS Ratio Chart

Foghorn Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial - 519.74 653.43 13.81 7.92

Foghorn Therapeutics Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.81 12.55 13.54 6.44 7.92

Competitive Comparison of Foghorn Therapeutics's PS Ratio

For the Biotechnology subindustry, Foghorn Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Foghorn Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Foghorn Therapeutics's PS Ratio falls into.



Foghorn Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Foghorn Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=5.21/0.814
=6.40

Foghorn Therapeutics's Share Price of today is $5.21.
Foghorn Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.81.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Foghorn Therapeutics  (NAS:FHTX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Foghorn Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Foghorn Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Foghorn Therapeutics (Foghorn Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
500 Technology Square, Suite 700, Cambridge, MA, USA, 02139
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Executives
Alfonso Quintas Cardama officer: Chief Medical Officer C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Samuel Agresta officer: Chief Medical Officer 784 MEMORIAL DR., CAMBRIDGE MA 02139
Lynch Thomas J. Jr. director 800 HOWARD AVENUE, YALE PHYSICIANS BUILDING, 2ND FLOOR, NEW HAVEN CT 06519
B Lynne Parshall director 2855 GAZELLE COURT, CARLSBAD CA 92010
Carlos Costa officer: Chief People Officer C/O FOGHORN THERAPEUTICS INC., 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Fanny Cavalie officer: Chief Strategy/Bus Ops Officer C/O FOGHORN THERAPEUTICS INC., 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Ian F Smith director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Michael Lacascia officer: Chief Legal Officer 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Carl Decicco officer: Chief Scientific Officer 100 BINNEY STREET, SUITE 610, CAMBRIDGE MA 02142
Flagship Ventures Opportunities Fund I General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Abu Dhabi Investment Authority 10 percent owner 211 CORNICHE STREET, PO BOX 3600, ABU DHABI C0 0000
Michael Mendelsohn director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Adam Koppel director C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Steven F. Bellon officer: See Remarks 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Jose Baselga director 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139